当前位置: 首页 >> 检索结果
161. Risk factors for metachronous colorectal cancer and advanced neoplasia following primary colorectal cancer: a systematic review and meta-analysis.
作者: Ye Zhang.;Amalia Karahalios.;Ye Kyaw Aung.;Aung Ko Win.;Alex Boussioutas.;Mark A Jenkins.
来源: BMC Gastroenterol. 2023年23卷1期421页
Identifying risk factors for metachronous colorectal cancer (CRC) and metachronous advanced neoplasia could be useful for guiding surveillance. We conducted a systematic review and meta-analysis to investigate risk factors for metachronous CRC and advanced neoplasia.
162. A meta-analysis of the prognostic impact of tissue golgi protein 73 (tGP73) in hepatocellular carcinoma.
To date, an increasing number of studies have revealed that GP73 may have prognostic value in liver cancer. However, most of the studies evaluated serum GP73, and the results regarding the prognostic value of tGP73 in liver cancer are still controversial. Therefore, in this meta-analysis, we aimed to determine whether tGP73 has any prognostic value in patients with HCC.
163. Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.
Oral nucleoside (acid) analogues (NAs) are recommended for patients with acute-on-chronic liver failure (ACLF) associated with hepatitis B virus (HBV-ACLF). The efficacy and safety of tenofovir (TDF) and entecavir (ETV) in these patients remain unclear.
164. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
作者: Zekun Liu.;Zhenzhen Zhao.;Xuefeng Ma.;Shousheng Liu.;Yongning Xin.
来源: BMC Gastroenterol. 2023年23卷1期384页
Nucleoside analogues are currently applied as a first-line treatment for chronic hepatitis B (CHB) patients. However, the long-term effects of this type of treatment on kidney and bone tissue need to be further investigated.
165. Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis.
Since the previous network meta-analysis assessing the efficacy of prokinetics for functional dyspepsia (FD), there have been a number of new studies and cinitapride is a new prokinetic agent for FD. This updated meta-analysis aimed to explore the efficacy and safety of prokinetics for FD.
166. Hepatic encephalopathy with proton pump inhibitor use in post tips patients: a systematic review and meta-analysis.
作者: Manesh K Gangwani.;Zohaib Ahmed.;Rizwan Ishtiaq.;Muhammad Aziz.;Anooja Rani.;Dushyant S Dahiya.;Fnu Priyanka.;Syeda F Arif.;Wade Lee-Smith.;Amir H Sohail.;Sumant Inamdar.;Mona Hassan.
来源: Minerva Gastroenterol (Torino). 2024年70卷3期353-358页
Hepatic encephalopathy (HE) after Trans-jugular intrahepatic portosystemic shunt (TIPS) is a common clinical problem. According to recent studies, Proton pump inhibitor (PPI) use can serve as an independent risk factor for HE. We performed a systematic review and meta-analysis to analyze the association between HE with PPI use versus without PPI use in patients undergoing TIPS.
167. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations.
作者: Jing Yu.;Yiming Lv.;Peng Yang.;Yizhou Jiang.;Xiangrong Qin.;Xiaoyong Wang.
来源: BMC Gastroenterol. 2023年23卷1期365页
Whether alcohol intake is associated with Helicobacter pylori (H. pylori) eradication failure remains controversial, and this meta-analysis was aimed at investigating the effect of alcohol on the risk of H. pylori eradication failure.
168. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
作者: Xinqiao Chu.;Yaning Biao.;Chengjiang Liu.;Yixin Zhang.;Chenxu Liu.;Ji-Zheng Ma.;Yufeng Guo.;Yaru Gu.
来源: BMC Gastroenterol. 2023年23卷1期346页
Therapeutic options for ulcerative colitis (UC) have increased since the introduction of biologics a few decades ago. Due to the wide range of biologics available, physicians have difficulty in selecting biologics and do not know how to balance the best drug between clinical efficacy and safety. This study aimed to compare the efficacy and safety of biologics in treating ulcerative colitis.
169. Risk factors for the mortality of hepatitis B virus-associated acute-on-chronic liver failure: a systematic review and meta-analysis.
作者: Hanyun Tu.;Rong Liu.;Anni Zhang.;Sufei Yang.;Chengjiang Liu.
来源: BMC Gastroenterol. 2023年23卷1期342页
Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) has been confirmed as a prevalent form of end-stage liver disease in people subjected to chronic HBV infection. However, there has been rare in-depth research on the risk factors for the mortality of HBV-ACLF. This study aimed at determining the risk factors for the mortality of HBV-ACLF.
170. Accessory hepatic vein recanalization for Budd-Chiari syndrome: a systematic review and meta-analysis.
Budd-Chiari syndrome (BCS) results when the outflow of the hepatic vein (HV) is obstructed. BCS patients exhibiting an accessory HV (AHV) that is dilated but obstructed can achieve significant alleviation of liver congestion after undergoing AHV recanalization. This meta-analysis was developed to explore the clinical efficacy of AHV recanalization in patients with BCS.
171. Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection.
The prevention of recurrence for patients with hepatocellular carcinoma after curative resection is still a great challenge in clinical practice. There are numerous studies that trying to search for favorable strategies to decrease the recurrence and prolong life span for these patients, whereas no consensus is reached till now. Herein, we aim to compare the efficacy between different reported treatments by network meta-analysis(NMA).
172. Association between tea consumption and colorectal cancer: a systematic review and meta-analysis of a population-based study.
作者: Yu Huang.;Qiang Chen.;Yating Liu.;Ruoxi Tian.;Xu Yin.;Yaoguang Hao.;Yang Yang.;Jian Yang.;Zongxuan Li.;Suyang Yu.;Hongyan Li.;Guiying Wang.
来源: BMC Gastroenterol. 2023年23卷1期294页
A meta-analysis study was performed to systematically assess the association between tea consumption and CRC risk.
173. Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis.
The incidence of HBV-negative and HCV-negative hepatocellular carcinoma (NBNC-HCC) is significantly increasing. However, their clinicopathologic features and prognosis remain elucidated. Our study aimed to compare the clinicopathologic characteristics and survival outcomes of NBNC-HCC with hepatitis virus-related HCC.
174. Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis.
作者: Ting Hu.;Cheng-Jiang Liu.;Xiaoming Yin.;WenJuan Tang.;LanFang Yin.;Hui Bai.;FangFang Liu.;Dan Wang.;YiLei Li.
来源: BMC Gastroenterol. 2023年23卷1期281页
The effectiveness of selective COX-2 inhibitors in preventing colorectal cancer recurrence has been demonstrated, however it is unknown how safe and successful they will be over the long term. As a result, we looked at the efficacy, safety, and consequences of adding COX-2 inhibitors to the treatment plan afterward.
175. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.
作者: Vivek C Goodoory.;Mais Khasawneh.;Christopher J Black.;Eamonn M M Quigley.;Paul Moayyedi.;Alexander C Ford.
来源: Gastroenterology. 2023年165卷5期1206-1218页
Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.
176. Efficacy and safety of Bifidobacterium quadruple viable tablets combined with mosapride citrate in the treatment of constipation in China: a systematic review and meta-analysis.
To analyze the efficacy and safety of Bifidobacterium quadruple viable tablets combined with mosapride citrate for the treatment of constipation.
177. Comparison of metal versus plastic stent for preoperative biliary drainage in patients with pancreatic cancer undergoing neoadjuvant therapy: a meta-analysis and systematic review.
This study was performed to compare a metal stent (MS) and plastic stent (PS) in terms of efficacy and complications during neoadjuvant therapy (NAT) and the perioperative period.
178. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
作者: Fausto Petrelli.;Alessandro Parisi.;Gianluca Tomasello.;Emanuele Mini.;Marcella Arru.;Alessandro Russo.;Ornella Garrone.;Shelize Khakoo.;Raffaele Ardito.;Michele Ghidini.
来源: BMC Gastroenterol. 2023年23卷1期212页
In metastatic pancreatic ductal adenocarcinoma (mPDAC), first line treatment options usually include combination regimens of folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX or mFOLFIRINOX) or gemcitabine based regimens such as in combination with albumin-bound paclitaxel (GEM + nab-PTX). After progression, multiple regimens including NALIRI + 5-FU and folinic acid, FOLFIRINOX, 5-FU-based oxaliplatin doublets (OFF, FOLFOX, or XELOX), or 5-FU-based monotherapy (FL, capecitabine, or S-1) are considered appropriate by major guidelines. This network meta-analysis (NMA) aimed to compare the efficacy of different treatment strategies tested as second-line regimens for patients with mPDAC after first-line gemcitabine-based systemic treatment.
179. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer.
作者: Suhail Yousuf.;Mengjie Qiu.;Lena Voith von Voithenberg.;Johannes Hulkkonen.;Igor Macinkovic.;Axel R Schulz.;Domenic Hartmann.;Florian Mueller.;Margarete Mijatovic.;David Ibberson.;Karam T AlHalabi.;Jenny Hetzer.;Simon Anders.;Bernhard Brüne.;Henrik E Mei.;Charles D Imbusch.;Benedikt Brors.;Mathias Heikenwälder.;Matthias M Gaida.;Markus W Büchler.;Andreas Weigert.;Thilo Hackert.;Susanne Roth.
来源: Gastroenterology. 2023年165卷4期891-908.e14页
As pancreatic ductal adenocarcinoma (PDAC) continues to be recalcitrant to therapeutic interventions, including poor response to immunotherapy, albeit effective in other solid malignancies, a more nuanced understanding of the immune microenvironment in PDAC is urgently needed. We aimed to unveil a detailed view of the immune micromilieu in PDAC using a spatially resolved multimodal single-cell approach.
180. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.
作者: Arman Shafiee.;Razman Arabzadeh Bahri.;Mohammad Mobin Teymouri Athar.;Fatemeh Afsharrezaei.;Mostafa Gholami.
来源: BMC Gastroenterol. 2023年23卷1期170页
Esophageal motility disorders are a group of disorders associated with dysfunctional swallowing resulting from impaired neuromuscular coordination. Phosphodiesterase 5 (PDE-5) inhibitors induce smooth relaxation and are proposed as a treatment option for esophageal motility disorders such as achalasia.
|